saypha ChiQ
Croma-Pharma GmbH · Decision date Jun 12, 2026
What did the FDA approve?
The FDA listed an approval decision dated 2026-06-12 for saypha® ChiQ™, submitted by Croma-Pharma GmbH under PMA number P250021. The product is categorized as an implant, dermal, for aesthetic use, with product code LMH, and is filed under the General and Plastic Surgery specialty. The source statement describes the device as indicated for cheek augmentation and restoring midface volume deficits in patients over the age of 21, administered by subcutaneous and/or supraperiosteal injection.
The record does not specify a supplement type or supplement reason, so the particular change addressed by this action is not identified in the supplied fields; the scope described is the indication and administration route quoted above. This is the labeled purpose reported in the source, not independent proof of safety or clinical effectiveness. The identifier alone does not establish a relationship to an earlier PMA, so none is asserted here; the entry is not a new approval of a whole system.
FDA approval order statement
saypha ChIQ is indicated for use in cheek augmentation and restoring midface volume deficits in patients over the age of 21. The device is indicated to be administered by subcutaneous and/or supraperiosteal injection.
- Regulatory pathway
- Original PMA
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 12, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250021
- Regulatory pathway
- Premarket approval application
- Applicant
- Croma-Pharma GmbH
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Jun 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Croma-Pharma GmbH
- Product code
- LMH
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250021 received
Application receipt date recorded by FDA.
P250021 · FDA decision
APPR
P250021/S001 · Related supplement
saypha ChiQ
P250021/S002 · Related supplement
saypha ChiQ
Timeline entries are records held by MedtechLedger for P250021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
Restylane ContourP140029/S058 | Q-Med AB | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Croma-Pharma GmbH
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Industriezeile 6, Leobendorf, 2100
Sources and methodology
- Original FDA record: P250021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




